National Cancer Institute; Notice of Meeting, 20488 [E9-10097]
Download as PDF
<![CDATA[
20488
Federal Register / Vol. 74, No. 84 / Monday, May 4, 2009 / Notices
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
tjames on PRODPC75 with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Board of
Scientific Advisors.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Board of Scientific Advisors.
Date: June 22–23, 2009.
Time: June 22, 2009, 8 a.m. to 6 p.m.
Agenda: Director’s Report: Ongoing and
New Business; Reports of Program Review
Group(s); and Budget Presentations; Reports
of Special Initiatives; RFA and RFP Concept
Reviews; and Scientific Presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor,
Conference Room 10, Bethesda, MD 20892.
Time: June 23, 2009, 8:30 a.m. to 12 p.m.
Agenda: Reports of Special Initiatives; RFA
and RFP Concept Reviews; and Scientific
Presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor,
Conference Room 10, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, PhD,
Executive Secretary, Director, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Rm. 8001,
Bethesda, MD 20892, 301–496–5147,
grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/bsa.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
VerDate Nov<24>2008
15:26 May 01, 2009
Jkt 217001
Dated: April 27, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–10097 Filed 5–1–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0199]
Pediatric Device Consortia Grant
Program
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of grant funds for the
support of the Office of Orphan
Products Development (OOPD) Pediatric
Device Consortia Grant Program
(PDCGP). The goal of the PDCGP is to
promote pediatric device development
by providing grants to nonprofit
consortia whose business model and
approach to device development will
either result in, or substantially
contribute to, market approval of
medical devices designed specifically
for use in children. Although
administered by the OOPD, this grant
program is intended to encompass
devices that could be used in all
pediatric conditions or diseases, not just
rare diseases. The pediatric population
(neonates, infants, children, and
adolescents) includes patients who are
21 years of age or younger at the time
of diagnosis or treatment.
DATES: Important dates are as follows:
1. The application due date is June 15,
2009.
2. The anticipated start date is
September 2009.
3. The opening date is May 1, 2009.
4. The expiration date is June 16,
2009.
FOR FURTHER INFORMATION AND
ADDITIONAL REQUIREMENTS CONTACT:
Linda C. Ulrich or Debra Y. Lewis,
Pediatric Device Consortia Grants
Program, Office of Orphan Products
Development (HF–35), Food and
Drug Administration, 5600 Fishers
Lane, rm. 6A–55, Rockville, MD
20857, 301–827–3666.
Camille Peake, Division of
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Acquisition Support and Grants,
Office of Acquisitions & Grant
Services (HFA–500), Food and Drug
Administration, 5630 Fishers Lane,
rm. 2139, Rockville, MD 20852,
301–827–7175.
For more information on this funding
opportunity announcement (FOA) and
to obtain detailed requirements, please
refer to the full FOA located at https://
grants.nih.gov/grants/guide/.
SUPPLEMENTARY INFORMATION:
I. Funding Opportunity Description
RFA–FD–009–007
Catalog of Federal Domestic Assistance
Number 93.103
A. Background
The development of pediatric medical
devices currently lags 5 to 10 years
behind the development of devices for
adults. Children differ from adults in
terms of their size, growth,
development, and body chemistry,
adding to the challenges of pediatric
device development. There currently
exists a great need for medical devices
designed specifically with children in
mind. Such needs include the original
development of pediatric medical
devices, as well as the specific
adaptation of existing adult devices for
children. Thus, as part of the 2007 Food
and Drug Administration Amendments
Act (FDAAA) legislation, Congress
passed the Pediatric Medical Device
Safety and Improvement Act of 2007.
Section 305 of FDAAA requires the
Secretary of Health and Human Services
to provide demonstration grants or
contracts to nonprofit consortia to
promote pediatric device development.
B. Research Objectives
The goal of FDA’s PDCGP is to
promote pediatric device development
by providing grants to nonprofit
consortia. The consortia will facilitate
the development, production, and
distribution of pediatric medical devices
by:
(1) Encouraging innovation and
connecting qualified individuals with
pediatric device ideas with potential
manufacturers;
(2) Mentoring and managing pediatric
device projects through the
development process, including product
identification, prototype design, device
development, and marketing;
(3) Connecting innovators and
physicians to existing Federal and nonFederal resources;
(4) Assessing the scientific and
medical merit of proposed pediatric
device projects; and
(5) Providing assistance and advice as
needed on business development,
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 74, Number 84 (Monday, May 4, 2009)]
[Notices]
[Page 20488]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-10097]
[[Page 20488]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Board of Scientific Advisors.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: National Cancer Institute Board of Scientific
Advisors.
Date: June 22-23, 2009.
Time: June 22, 2009, 8 a.m. to 6 p.m.
Agenda: Director's Report: Ongoing and New Business; Reports of
Program Review Group(s); and Budget Presentations; Reports of
Special Initiatives; RFA and RFP Concept Reviews; and Scientific
Presentations.
Place: National Institutes of Health, Building 31, 31 Center
Drive, 6th Floor, Conference Room 10, Bethesda, MD 20892.
Time: June 23, 2009, 8:30 a.m. to 12 p.m.
Agenda: Reports of Special Initiatives; RFA and RFP Concept
Reviews; and Scientific Presentations.
Place: National Institutes of Health, Building 31, 31 Center
Drive, 6th Floor, Conference Room 10, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, PhD, Executive Secretary,
Director, Division of Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116 Executive Boulevard,
8th Floor, Rm. 8001, Bethesda, MD 20892, 301-496-5147,
grayp@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: deainfo.nci.nih.gov/advisory/bsa.htm, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 27, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-10097 Filed 5-1-09; 8:45 am]
BILLING CODE 4140-01-P
